[ ERA-NET E-Rare | Research funding for collaborative projects on Rare Diseases – Pre-announcement ]

E-Rare is an ERA-NET initiative aimed at coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implementing the objectives of the International Rare Disease Research Consortium (IRDiRC). E-Rare is co-financed by the European Commission (Horizon 2020) and 22 countries, including Switzerland (via the SNSF).

The 2020 call on “PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES” focuses on the following topics:

1. Development of novel therapies in a preclinical setting.
2. Use of disease models suitable for medicinal product’s development.
3. Development of predictive and pharmacodynamics (PD) biomarkers in a preclinical setting.
4. Proof of principle studies fostering an early (pre-clinical) stage of drug development.

• Consortium: 4-6 principal investigators (PIs) from at least 3 different participating countries. Exception: you can involve 7-8 PIs if at least 1-2 are based in Czech Republic, Slovakia, Hungary, Lithuania, Poland, and Turkey and/or are early career researchers. Applicants from academia, clinical/public health sector, SMEs and patient advocacy organisations must be eligible for funding by their national funding organisations.
• Swiss-based applicants: contact SNSF (Christoph Meier, +41 31 308 23 62, [email protected]) to verify yours and your consortium’s eligibility.

• Opening of the call: 13 December 2019
• Deadline for pre-proposals: 12 February 2020
• Invitation to full proposals: April 2020
• Deadline for full proposals:  16 June 2020
• Deadline for rebuttals: 28 July 2020
• Decision: October 2020